John Hele
Analyst · risks and uncertainties, including those described from time to time in MetLife's filings with the U.S. Securities and Exchange Commission, including in the risk factors section of those filings. MetLife specifically disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. With that, I would like to turn the call over to John Hall, Head of Investor Relations
Thank you, Steve, and good morning. Today, I’ll cover our second quarter results including a discussion of our insurance underwriting margins, investment spreads, expenses and business highlights. I will then conclude with some comments on potential impacts on separation as well as cash and capital. In addition to our earnings release and quarterly financial supplement, last night, we released disclosure labeled 2Q17 Supplemental Slides that provide a walk from net income to operating earnings for the quarter. I will speak to these slides later in my presentation. We will continue to release supplemental slides when we have complex elements in a quarter. Operating earnings in the second quarter were $1.4 billion or a $1.30 per share. This quarter includes four notable items totaling the negative $41 million that we highlighted in our news release and quarterly financial supplement. Adjusted for all notable items in both periods, operating earnings were up 3% year-over-year. On a per share basis, operating earnings adjusted for all notable items were $1.34, up 6% year-over-year. Turning to our bottom-line results. We had second quarter net income of $838 million or $0.77 per share. Net income was $569 million lower than operating earnings, primarily because of net derivative losses of $284 million after tax and costs related to the Brighthouse Financial separation of $216 million after tax. For more details about the difference between net income and operating earnings, please refer to page three in our supplemental slide disclosure this quarter. Page four in the supplemental slides shows the attribution of the after tax net derivative loss. I would highlight three main drivers. Number one, foreign currency derivative loss of $188 million after tax, primarily due to the weakening of the U.S. dollar against several currencies including the euro, the British pound and the Canadian dollar. MetLife invests in non-U.S. bonds for our U.S. portfolios to provide enhanced risk diversification and incremental yield. These bonds are swapped back to the U.S. dollar, so they economically match the U.S. dollar liabilities they support. Since certain of these hedges do not qualify for hedge accounting, asymmetrical accounting treatment between the bonds and the related currency swaps drives volatility in our GAAP net income. Importantly, this FX volatility in GAAP does not exist in statutory accounting. Number two. The VA hedge program accounted for an after tax loss of $340 million, mainly in Brighthouse Financial, including the $116 million related to asymmetrical and non-economic factors. Losses related to other risks were driven by the non-market drops in account value, primarily the deduction of fees. These losses were offset by number three, interest rate net derivative gain of $295 million after-tax due to the decline in long-term rates in the quarter. Overall, $114 million of the $284 million net derivative loss was due to asymmetrical and non-economic accounting. Under U.S. GAAP, this continues to be a significant component of our derivative gains and losses each quarter as the derivatives are mark-to-market, but a significant portion of MetLife’s VA and life liabilities are not. You can find the total impact of $203 million of adjustments for asymmetrical and non-economic accounting on our net income in the second page of tables attached to the press release. Book value per share excluding AOCI other than FCTA was $51.03 as of June 30th, up 1% versus the sequential quarter as of March 31st. With respect to second quarter underwriting margins, total Company earnings were lower by approximately $0.02 per share versus the prior quarter, after adjusting for notable items in both periods. Underwriting in Brighthouse Financial accounted for approximately $0.05 of the total decrease. This was primarily due to the previously disclosed impact from the loss of the aggregation benefit in variable in universal life and the second quarter 2016 modeling changes. Excluding Brighthouse Financial, underwriting earnings were higher by proximately $0.03 per share year-over-year, this is due to favorable underwriting in the U.S., primarily in group non-medical health and retail life within MetLife Holdings. The group non-medical health interest adjusted benefit ratio was 76.9%, favorable to the prior year quarter of 78.9% and within the 2017 annual target of 76% to 81%. Favorable underwriting results were primarily driven by dental. MetLife Holdings interest adjusted benefit ratio for life products was $51.1%, driven by favorable mortality. This result was favorable to the prior year quarter of 59.4% after adjusting for notable items and below the targeted range of 53% to 58%. Turning to investment margins. The weighted average of the three product spreads presented in our QSS was 150 basis points in the quarter, down 20 basis points year-over-year. Pre-tax variable investment income or VII, was $279 million versus $285 million in the prior year quarter, as lower prepayments were offset by stronger private equity performance. Product spreads excluding VII were 122 basis points this quarter, down 18 basis points year-over-year. Lower core yields accounted for most of this decline. Overall, lower investment margins in the quarter accounted for approximately $0.09 of EPS underperformance year-over-year. The operating expense ratio in the current quarter was 22.0% and 21.1% adjusting for all notable items, benefitting from higher pension risk transfers sales and the sale of the MetLife Premier Client Group to MassMutual in the prior year. Operating expense margins, adjusting for all notable items, were less favorable to the prior year quarter by $0.02 per share. Costs associated with the build of Brighthouse Financial as a standalone company, higher variable expenses and a prior year adjustment which reduced employee benefits, were partially offset by lower operating expenses due to sale of MetLife Premier Client Group. In regards to our unit cost initiative or UCI, our first half expense savings are generally in line with expectations. Consistent with prior guidance, as provided at our 2016 Investor Day, we believe full year 2017 UCI expense savings will be masked by the impacts of our onetime investments in stranded overhead with the net unfavorable impact to operating expenses of approximately $100 million. Group Benefits reported operating earnings of $203 million, up 10% and 9% adjusting for notable items in the prior year quarter. The primary drivers are strong non-medical health underwriting and volume growth. Group Benefits operating PFOs were $4.2 billion, up 3% year-over-year, driven by growth across all markets. PFO growth was negatively impacted by the loss of a large dental contract in this quarter. Excluding this impact, PFO growth was 5% and at the high end of our guidance of 3% to 5%. Group Benefits sales were up 30% year-to-date with growth across all products. We continue to see particular strength in the jumbo market due to more quote activity and higher closing ratios, while persistency continued to be favorable. Retirement and Income Solutions or RIS, reported operating earnings of $268 million, up 3% due to reserve adjustment in the prior year quarter. Excluding all notable items, operating earnings were down 5% due to lower investment margins driven by continued spread compression. RIS operating PFOs were $1.2 billion, driven by two large pension risk transfers sales. Excluding PRT, PFOs were down 1% year-over-year. We continue to see a good PRT pipeline and expect 2017 to be an active year for transactions of all sizes. Our approach will continue to balance growth with an efficient use of capital. Property & Casualty or P&C, operating earnings were $28 million, up $30 million compared to the second quarter of 2016, and up $15 million after adjusting for notable items in the prior year quarter. This result was due to improved auto underwriting, particularly offset -- partially offset by non-catastrophe weather losses in homeowners. Our P&C combined ratio excluding cats and prior year development with 88.2% better than the prior year quarter of 90.8%. We continue to see improvement in our underwriting auto results, which posted a combined ratio excluding cats and prior year development of 94.2%, well below the 101.0% in the prior year quarter. Auto results have benefited from targeted rate increases over the last 12 months of 7% to 8%. And we expect to take similar rate actions in the immediate future. P&C operating PFOs were $887 million, up 1% year-over-year primarily the result of the auto rate increases. Overall, P&C sales were also up 1%, reflective of price increases and management actions to drive value. Turning to Asia. Operating earnings were $310 million, up 20% but down 4% on a constant currency basis after adjusting for notable items in both quarters. Volume growth was offset by higher expenses and less favorable underwriting. Asia operating PFOs were $2.0 billion, down 1%, but up 1% on a constant currency basis. Asia sales were down 4% on a constant currency basis, reflecting management’s action to improve value in targeted markets. In Japan, sales were down 5% as the shift to foreign currency whole life continued. FX life sales were up 43%, while yen life sales were down 66%. FX life sales accounted for 85% of total life sales in Japan this quarter. A&H sales in Japan were down 9% in advance of the introduction of our refreshed medical products Flexi S and Flexi Gold S, which were launched in July, which we expect will have improved sales in the second half of the year. Emerging market sales in Asia were up 21%, driven by continued growth in China, following the successful launch of the whole new life critical illness product called Safeguarding Your Health, which is the first in the market to offer our full end-to-end health solution. Latin America reported operating earnings of $154 million, up 12% and 14% on a constant currency basis, the key drivers were volume growth, lower taxes and higher investment margins. We expect lower operating earnings in the second half of the year as the full impact of the Provida fee reduction implemented in June takes hold and the favorable market performance in the first half returns to normal. Latin America operating PFOs were $928 million, up 2% on both the reported and constant currency basis. This growth reflects the non-renewal of a low margin large group contract in the second quarter of 2017. Excluding this non-renewal, PFOs were up 8% driven by strong growth in Mexico. Total sales for the region were down 28% on a constant currency basis due to large employee benefit sale in Mexico in the prior year quarter. Excluding this employee benefit sale, sales were up 3%. EMEA operating earnings were $72 million, up 13% and 24% on a constant currency basis. The key drivers were favorable expense margins and underwriting. EMEA operating PFOs were $625 million, down 1% but 3% on a constant currency basis, driven by growth in Turkey and employee benefits in the UK. Total EMEA sales decreased 5% on a constant currency basis, mainly due to competitive pressures in the Gulf as well as the recently exited Wealth Management business in the UK. As a reminder, we had guided to flat EMEA sales in 2017, mainly due to uncertainty in the UK, following Brexit. Those challenges mainly related to low interest rates have proven to be server. While the Gulf has been a challenge, we continue to see strong growth in other parts of the Middle East, particularly Turkey and Egypt, and also in A&H business across the region, which now represents nearly a quarter of overall EMEA sales. MetLife Holdings reported operating earnings of $235 million, compared to $33 million operating loss in the second quarter of 2016. The second quarter of 2016 operating loss was due to a $304 million negative impact, primarily from the separation related items and other insurance adjustments. Operating earnings in the second quarter of 2017 include a $40 million negative impact from separation related activities that was offset in Brighthouse Financial. Excluding notable items in both periods, operating earnings were up 1%, driven by favorable equity market impact and underwriting, mostly offset by lower investment margins. MetLife Holdings operating PFOs were $1.4 billion, down 17%, mostly due to the sale of MetLife Premier Client Group, which included the Company’s affiliated broker dealer unit. As previously guided, we expect operating PFOs to decline by approximately 12% in 2017 versus 2016. Corporate & Other reported an operating loss of $146 million compared to an operating loss of $243 million in the second quarter of 2016. Adjusting for notable items in both periods, the operating loss was $115 million compared to loss of $244 million in the prior year quarter, driven by a lower effective tax rate and favorable investment margins. As for the Company’s effective tax rate, it was 20.6% and 21.7% after adjusting for favorable tax audit in the quarter. We still expect the Company’s 2017 effective tax rate to be between 21% and 22%, as previously guided. The primary reason for the company’s low tax rate has been due to the tax preference items in the U.S. and foreign operations tax at lower rates in the U.S. tax rate of 35%. Brighthouse Financial operating earnings were $283 million, down 5% or 31% after adjusting for notable items in both quarters. The decline in earnings when adjusted for notable items was primarily driven by lower net investment income from reduced interest rate, swap and securities lending books, lower universal life for secondary guarantees earnings after the model changes in the second quarter of 2016 and higher expenses. The higher expense activity is related to the build-out of Brighthouse as a standalone basis. As a standalone company, Brighthouse Financial expects corporate expenses to be $175 million to $225 million higher in initial year, post-separation as compared to the 2015 levels, as well as incremental interest expense from debt service. Overall annuity sales were down 8%, and life sales were down 64%, mostly resulting from the sale of the MetLife Premier Client Group, in July of 2016. Sales of the Company’s index-linked annuity product, Shield Level Selector, remained strong. In the second quarter of 2017, sales were $570 million, up 28% year-over-year and over $1 billion for the first half of 2017. As a reminder, Brighthouse Financial segment results within MetLife’s financial statements do not match the financial statements of Brighthouse Financial, Inc. and related companies shown in the most recent Brighthouse Financial Form 10, due to accounting timing differences. Next, I would like to comment on some of the expected third quarter financial impacts, as a result of the Brighthouse Financial separation. The separation will result in Brighthouse’s historical results being reported as discontinued operations. Upon separation, the remaining ownership interest in Brighthouse Financial will be accounted for under the equity method with changes in the fair value reported in net investment gains and losses. To give you an indication, if Brighthouse Financial closes at $70 per share at the end of the third quarter, we would anticipate realized losses of approximately $120 million post-tax. In addition, there are $800 million of losses post-tax related to intercompany transactions and tax-related items. Additionally, we anticipate an operating tax charge of approximately $200 million related to the repatriation of cash as a result of the separation, partially offset by a tax benefit associated with dividend from our foreign operations. I will now discuss our cash and capital position. Cash and liquid assets at the holding companies were approximately $4.6 billion at June 30th, which is up from $3.8 billion at March 31st. This increase reflects $615 million of net proceeds from the spin, as well as subsidiary dividends, share repurchases, payment of our quarterly common dividend, and other holding company expenses. As announced in the MetLife and Brighthouse Financial Form 8-Ks filed last night, MetLife will receive a cash remittance of approximately $1.8 billion from Brighthouse Financial prior to the completion of the spin-off. This brings MetLife’s total net cash remittance to $3.0 billion. Of the remaining $1.2 billion, $295 million was received in the fourth quarter 2016, $640 million received this quarter, the remaining relates to proceeds received from unwinding of certain reinsurance transactions, which we recognize at the holding company in 2018. This is lower than our initially planned range of $3.3 billion to $3.8 billion to adjust for Brighthouse Financial’s planned reserve increases for refinements in legacy actuarial models. These refinements bring to a close an extensive internal and external review. Next, I would like to provide you with an update on our capital position. For our U.S. companies including Brighthouse, preliminary year-to-date second quarter statutory operating earnings is approximately $1.8 billion, up 67% and preliminary net income is $538 million up 6%. MetLife’s U.S. companies excluding Brighthouse preliminary statutory operating earnings were $1.9 billion, up 67% and preliminary net income was $1.4 billion, up 83%. Both are higher primarily due to favorable underwriting and lower expenses, partially offset by lower net investment income. We estimate that our total U.S. statutory adjusted capital was approximately $26 billion as of June 30th, up 6%. MetLife’s preliminary statutory adjusted capital was $20 billion, up 3% from December 31st, 2016 primarily due to higher net income, partially offset by dividend paid to the holding company. Brighthouse Financial expects, combined statutory total adjusted capital to be approximately $6.4 billion as of June 30th, an increase of $2.2 billion from March 31st. This increase was driven primarily by spin-off related transaction at the life holding companies including a $600 million capital contribution to Brighthouse Life Insurance Company on June 30th and proceeds to the Brighthouse bond offering. Brighthouse Financial estimates that at June 30th, variable annuity assets above CTE95 would be approximately $2.3 billion pro forma for the separation. For MetLife Japan, the solvency margin ratio was 957% as of March 31st which is laid as public data. Overall, MetLife had a strong second quarter in 2017, highlighted by favorable impacts in equity markets and solid underwriting in the U.S. as well as a continued focus on expense management. In addition, our cash and capital position remains strong and we remain confident that the actions we’re taking to implement our strategy will drive free cash flow and create long-term sustainable value to our shareholders. And with that, I’ll turn it back to the operator for your questions.